%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Thomas W. von Geldern, Howard E. Morton, Rick F. Clark, Brian S. Brown, Kelly L. Johnston, Louise Ford, Sabine Specht, Robert A. Carr, Deanne F. Stolarik, Junli Ma, Matthew J. Rieser, Dominique Struever, Stefan J. Frohberger, Marianne Koschel, Alexandra Ehrens, Joseph D. Turner, Marc P. Hübner, Achim Hoerauf, Mark J. Taylor, Stephen A. Ward, Kennan Marsh, Dale J. Kempf
Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity
www.plosntds.org
www.plosntds.org
endstream
endobj
3 0 obj
<>
endobj
4 0 obj
<>/XObject<>>>
endobj
6 0 obj
[18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R]
endobj
18 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref001)>>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref002)>>
endobj
20 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref003)>>
endobj
21 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref004)>>
endobj
22 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref005)>>
endobj
23 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref006)>>
endobj
24 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref007)>>
endobj
25 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref008)>>
endobj
26 0 obj
<>/Border[0 0 0]/A 27 0 R>>
endobj
27 0 obj
<>
endobj
7 0 obj
<>stream
q
Q
q
12.0189 54.5953 583.087 707.414 re
W* n
q
1 0 0 1 12.0189 54.5953 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
0.955 g
0.0001 w
200 714 m
576 714 l
576 572 l
200 572 l
f*
0.83 0.64 0.02 0 k
529.739 483.931 m
534.501 483.931 l
h
f*
536.769 483.931 m
541.531 483.931 l
h
f*
490.11 392.939 m
494.872 392.939 l
h
f*
533.424 366.917 m
538.186 366.917 l
h
f*
328.706 353.934 m
333.468 353.934 l
h
f*
460.743 236.92 m
465.506 236.92 l
h
f*
305.461 158.91 m
310.224 158.91 l
h
f*
312.491 158.91 m
317.254 158.91 l
h
f*
0 g
1 j
1 J
10 0 0 10 209.99 696.983 cm
BT
/F9 1 Tf
-0.004 Tc
1 TL
0 0 Td
(that)Tj
1.7801 0 Td
(of)Tj
1.0148 0 Td
(doxycycline,)Tj
5.1874 0 Td
(its)Tj
1.1452 0 Td
(potency)Tj
3.3958 0 Td
(is)Tj
0.8448 0 Td
(not)Tj
1.576 0 Td
(ideal,)Tj
2.3414 0 Td
(and)Tj
1.7291 0 Td
(it)Tj
0.7881 0 Td
(suffers)Tj
2.8403 0 Td
(from)Tj
2.2053 0 Td
(poor)Tj
2.1203 0 Td
(oral)Tj
1.7801 0 Td
(bioavailability.)Tj
-28.7487 -1.2982 Td
(By)Tj
1.2529 0 Td
(appropriate)Tj
4.8812 0 Td
(derivatization)Tj
5.7316 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(4-OH)Tj
2.9537 0 Td
(group)Tj
2.6079 0 Td
(of)Tj
1.0148 0 Td
(TylA)Tj
2.2167 0 Td
(\(on)Tj
1.6157 0 Td
(the)Tj
1.4683 0 Td
(mycaminose)Tj
5.2781 0 Td
(sugar\))Tj
2.7212 0 Td
(we)Tj
-34.2252 -1.2983 Td
(were)Tj
2.1259 0 Td
(able)Tj
1.8255 0 Td
(to)Tj
1.0262 0 Td
(improve)Tj
3.5829 0 Td
(oral)Tj
1.7802 0 Td
(absorption)Tj
4.5354 0 Td
(while)Tj
2.3697 0 Td
(simultaneously)Tj
6.2419 0 Td
(increasing)Tj
4.3313 0 Td
(anti-)Tj
/F10 1 Tf
()Tj
/F9 1 Tf
-27.819 -1.3039 Td
(potency.)Tj
3.6169 0 Td
(Optimization)Tj
5.6069 0 Td
(of)Tj
1.0148 0 Td
(this)Tj
1.6725 0 Td
(substituent)Tj
4.6374 0 Td
(with)Tj
2.0013 0 Td
(a)Tj
0.6519 0 Td
(focus)Tj
2.3301 0 Td
(on)Tj
1.2756 0 Td
(metabolic)Tj
4.1442 0 Td
(stability)Tj
3.3505 0 Td
(led)Tj
1.4173 0 Td
(to)Tj
1.0262 0 Td
(the)Tj
-32.7456 -1.2983 Td
(identification)Tj
5.5842 0 Td
(of)Tj
1.0148 0 Td
(ABBV-4083,)Tj
5.2384 0 Td
(the)Tj
1.4683 0 Td
(4-\(4F-benzyl\))Tj
6.0661 0 Td
(analog.)Tj
3.0841 0 Td
(ABBV-4083)Tj
5.0116 0 Td
(is)Tj
0.8447 0 Td
(exquisitely)Tj
4.4617 0 Td
(active)Tj
-32.7739 -1.2982 Td
(against)Tj
/F10 1 Tf
3.0273 0 Td
()Tj
/F9 1 Tf
(,)Tj
4.7112 0 Td
(with)Tj
1.9956 0 Td
(an)Tj
1.2018 0 Td
(improved)Tj
4.1103 0 Td
(pharmacokinetic)Tj
6.9788 0 Td
(profile.)Tj
3.0671 0 Td
(This)Tj
1.9842 0 Td
(analog)Tj
2.8573 0 Td
(outperforms)Tj
-29.9336 -1.3039 Td
(doxycycline)Tj
4.9605 0 Td
(in)Tj
1.0375 0 Td
(several)Tj
2.9367 0 Td
(animal)Tj
2.965 0 Td
(models)Tj
3.1068 0 Td
(of)Tj
1.0148 0 Td
(filariasis;)Tj
3.7417 0 Td
(in)Tj
1.0374 0 Td
(particular)Tj
4.1103 0 Td
(it)Tj
0.7823 0 Td
(clears)Tj
2.4832 0 Td
(the)Tj
1.4683 0 Td
(bacteria)Tj
3.3789 0 Td
(effec-)Tj
-33.0234 -1.2983 Td
(tively)Tj
2.364 0 Td
(with)Tj
2.0013 0 Td
(substantially)Tj
5.2044 0 Td
(shortened)Tj
4.2065 0 Td
(dosing)Tj
2.897 0 Td
(regimens.)Tj
4.1216 0 Td
(Preclinical)Tj
4.4333 0 Td
(efficacy)Tj
3.2202 0 Td
(and)Tj
1.7291 0 Td
(safety)Tj
2.4831 0 Td
(studies)Tj
-32.6605 -1.2983 Td
(indicate)Tj
3.4128 0 Td
(that)Tj
1.7745 0 Td
(ABBV-4083)Tj
5.0116 0 Td
(may)Tj
1.9276 0 Td
(have)Tj
2.0636 0 Td
(a)Tj
0.652 0 Td
(desirable)Tj
3.7814 0 Td
(profile)Tj
2.8403 0 Td
(as)Tj
1.0147 0 Td
(a)Tj
0.652 0 Td
(novel,)Tj
2.6305 0 Td
(next-generation)Tj
6.5934 0 Td
(anti-)Tj
-32.3544 -1.2982 Td
(filarial)Tj
2.7722 0 Td
(agent.)Tj
ET
Q
q
1 j
1 J
0.0001 w
11.9999 0 0 11.9999 200.012 527.981 cm
BT
/F3 1 Tf
-0.0033 Tc
1 TL
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 200.012 510.973 cm
BT
/F9 1 Tf
-0.004 Tc
1 TL
0 0 Td
(The)Tj
1.7801 0 Td
(filarial)Tj
2.7723 0 Td
(worm)Tj
2.6022 0 Td
(diseases)Tj
3.3788 0 Td
(onchocerciasis)Tj
6.0661 0 Td
(\(river)Tj
2.8403 0 Td
(blindness\))Tj
4.7452 0 Td
(and)Tj
1.7291 0 Td
(lymphatic)Tj
4.2066 0 Td
(filariasis)Tj
3.5206 0 Td
(\(LF,)Tj
1.8482 0 Td
(ele-)Tj
-35.4895 -1.2982 Td
(phantiasis\),)Tj
5.193 0 Td
(though)Tj
3.0727 0 Td
(not)Tj
1.5761 0 Td
(typically)Tj
3.5603 0 Td
(lethal,)Tj
2.6192 0 Td
(produce)Tj
3.5206 0 Td
(substantial)Tj
4.5014 0 Td
(morbidity,)Tj
4.4673 0 Td
(social)Tj
2.4605 0 Td
(stigma)Tj
2.863 0 Td
(and)Tj
1.7291 0 Td
(loss)Tj
-35.5632 -1.2983 Td
(of)Tj
1.0091 0 Td
(economic)Tj
4.1329 0 Td
(opportunity)Tj
5.0286 0 Td
(in)Tj
1.0261 0 Td
(tropical)Tj
3.2825 0 Td
(and)Tj
1.7235 0 Td
(subtropical)Tj
4.6714 0 Td
(regions)Tj
3.1578 0 Td
(throughout)Tj
4.7735 0 Td
(the)Tj
1.4627 0 Td
(globe)Tj
2.3641 0 Td
([)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(2)Tj
0 g
(].)Tj
2.296 0 Td
(Nearly)Tj
-34.9282 -1.2982 Td
(150)Tj
1.644 0 Td
(million)Tj
3.1238 0 Td
(people)Tj
2.8516 0 Td
(are)Tj
1.4514 0 Td
(currently)Tj
3.8834 0 Td
(infected)Tj
3.4242 0 Td
(with)Tj
1.9956 0 Td
(these)Tj
2.2564 0 Td
(parasites,)Tj
3.9118 0 Td
(with)Tj
1.9955 0 Td
(a)Tj
0.652 0 Td
(greater)Tj
3.0104 0 Td
(number)Tj
3.4185 0 Td
(at)Tj
0.9525 0 Td
(risk;)Tj
-34.5711 -1.304 Td
(more)Tj
2.3414 0 Td
(than)Tj
2.0295 0 Td
(40)Tj
1.1679 0 Td
(million)Tj
3.1238 0 Td
(suffer)Tj
2.4774 0 Td
(from)Tj
2.2054 0 Td
(symptomatic)Tj
5.4198 0 Td
(disease.)Tj
3.2428 0 Td
(Current)Tj
3.4242 0 Td
(treatments)Tj
4.5014 0 Td
(for)Tj
1.3833 0 Td
(these)Tj
-31.3169 -1.2982 Td
(neglected)Tj
4.3936 0 Td
(tropical)Tj
3.2825 0 Td
(diseases)Tj
3.7701 0 Td
(\(NTD's\))Tj
3.5603 0 Td
(typically)Tj
3.5603 0 Td
(involve)Tj
3.1237 0 Td
(periodic)Tj
3.5263 0 Td
(mass)Tj
2.194 0 Td
(drug)Tj
2.109 0 Td
(administration)Tj
-29.5198 -1.2983 Td
(\(MDA\),)Tj
3.4355 0 Td
(with)Tj
2.0013 0 Td
(the)Tj
1.4683 0 Td
(goal)Tj
1.8709 0 Td
(of)Tj
1.0148 0 Td
(reducing)Tj
3.7757 0 Td
(disease)Tj
3.016 0 Td
(prevalence)Tj
4.4901 0 Td
(and)Tj
1.7291 0 Td
(ideally)Tj
2.8176 0 Td
(triggering)Tj
4.1612 0 Td
(elimination.)Tj
5.074 0 Td
(Popu-)Tj
-34.8545 -1.3039 Td
(lations)Tj
2.8799 0 Td
(in)Tj
/F10 1 Tf
1.0375 0 Td
(\r )Tj
/F9 1 Tf
(endemic)Tj
8.5663 0 Td
(regions)Tj
3.1634 0 Td
(are)Tj
1.4457 0 Td
(administered)Tj
5.4935 0 Td
(an)Tj
1.2018 0 Td
(annual)Tj
2.9594 0 Td
(or)Tj
1.0998 0 Td
(semi-annual)Tj
5.1761 0 Td
(dose)Tj
2.0409 0 Td
(of)Tj
-35.0643 -1.2983 Td
(ivermectin;)Tj
4.7394 0 Td
(LF-endemic)Tj
5.074 0 Td
(communities)Tj
5.4822 0 Td
(normally)Tj
3.8494 0 Td
(receive)Tj
3.0047 0 Td
(a)Tj
0.652 0 Td
(combination)Tj
5.3518 0 Td
(of)Tj
1.0148 0 Td
(albendazole)Tj
4.9266 0 Td
(with)Tj
-34.0949 -1.2982 Td
(ivermectin)Tj
4.5183 0 Td
(in)Tj
1.0319 0 Td
(sub-Saharan)Tj
5.193 0 Td
(Africa)Tj
2.6872 0 Td
(or)Tj
1.0999 0 Td
(with)Tj
1.9955 0 Td
(diethylcarbamazine)Tj
8.039 0 Td
(elsewhere)Tj
4.1046 0 Td
([)Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
(].)Tj
1.6044 0 Td
(More)Tj
2.4151 0 Td
(recently,)Tj
3.634 0 Td
(the)Tj
-36.3229 -1.304 Td
(World)Tj
2.8346 0 Td
(Health)Tj
2.9083 0 Td
(Organization)Tj
5.5219 0 Td
(\(WHO\))Tj
3.3732 0 Td
(has)Tj
1.5363 0 Td
(explored)Tj
3.7021 0 Td
(the)Tj
1.4626 0 Td
(use)Tj
1.5307 0 Td
(of)Tj
1.0092 0 Td
(triple-therapy)Tj
5.7146 0 Td
(employing)Tj
4.4673 0 Td
(ivermec-)Tj
-34.0608 -1.2982 Td
(tin,)Tj
1.559 0 Td
(diethylcarbamazine)Tj
8.039 0 Td
(and)Tj
1.7291 0 Td
(albendazole,)Tj
5.159 0 Td
(recommending)Tj
6.3666 0 Td
(its)Tj
1.1452 0 Td
(use)Tj
1.5307 0 Td
(in)Tj
1.0375 0 Td
(specific)Tj
3.1918 0 Td
(settings)Tj
3.2428 0 Td
([)Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
(].)Tj
-33.0007 -1.2983 Td
(Recently-approved)Tj
7.7612 0 Td
(moxidectin)Tj
4.7678 0 Td
([)Tj
0.83 0.64 0.02 0 k
(5)Tj
0 g
(])Tj
1.3776 0 Td
(may)Tj
1.9276 0 Td
(offer)Tj
2.0976 0 Td
(some)Tj
2.3301 0 Td
(advantage)Tj
4.2406 0 Td
(as)Tj
1.0148 0 Td
(a)Tj
0.6519 0 Td
(replacement)Tj
5.1534 0 Td
(for)Tj
1.3833 0 Td
(ivermectin)Tj
-32.7059 -1.3039 Td
(with)Tj
1.9955 0 Td
(a)Tj
0.652 0 Td
(more)Tj
2.3414 0 Td
(sustained)Tj
3.9741 0 Td
(response.)Tj
3.9572 0 Td
(These)Tj
2.5625 0 Td
(agents)Tj
2.7552 0 Td
(primarily)Tj
3.9685 0 Td
(kill)Tj
1.474 0 Td
(first-stage)Tj
4.1386 0 Td
(larvae)Tj
2.5852 0 Td
(\(microfilariae,)Tj
-30.4042 -1.2983 Td
(mf\))Tj
1.6667 0 Td
(and)Tj
1.7291 0 Td
(temporarily)Tj
4.9323 0 Td
(sterilize)Tj
3.2882 0 Td
(adult)Tj
2.2563 0 Td
(worms,)Tj
3.1861 0 Td
(but)Tj
1.5534 0 Td
(do)Tj
1.2586 0 Td
(not)Tj
1.5704 0 Td
(clear)Tj
2.1203 0 Td
(the)Tj
1.4683 0 Td
(primary)Tj
3.4583 0 Td
(infection.)Tj
4.0138 0 Td
(Conse-)Tj
-32.5018 -1.2982 Td
(quently,)Tj
3.4525 0 Td
(MDA)Tj
2.5285 0 Td
(must)Tj
2.228 0 Td
(be)Tj
1.1509 0 Td
(repeated)Tj
3.6397 0 Td
(at)Tj
0.9524 0 Td
(regular)Tj
3.0614 0 Td
(intervals)Tj
3.6226 0 Td
(to)Tj
1.0262 0 Td
(successfully)Tj
4.8642 0 Td
(affect)Tj
2.3754 0 Td
(disease)Tj
3.0161 0 Td
(prevalence.)Tj
-30.7217 -1.2983 Td
(Agents)Tj
3.0047 0 Td
(that)Tj
1.7744 0 Td
(effectively)Tj
4.2123 0 Td
(kill)Tj
1.4797 0 Td
(adult)Tj
2.2507 0 Td
(worms)Tj
2.965 0 Td
(could)Tj
2.4491 0 Td
(greatly)Tj
2.914 0 Td
(speed)Tj
2.4718 0 Td
(efforts)Tj
2.7609 0 Td
(toward)Tj
3.0388 0 Td
(elimination)Tj
4.8472 0 Td
(of)Tj
-35.3648 -1.3039 Td
(these)Tj
2.2506 0 Td
(diseases,)Tj
3.6057 0 Td
(and)Tj
1.7291 0 Td
(thus)Tj
1.9389 0 Td
(are)Tj
1.4457 0 Td
(a)Tj
0.6519 0 Td
(critical)Tj
2.9537 0 Td
(priority)Tj
3.2768 0 Td
(for)Tj
1.3833 0 Td
(new)Tj
1.8766 0 Td
(filariasis)Tj
3.5149 0 Td
(drug)Tj
2.1146 0 Td
(development.)Tj
5.6353 0 Td
(It)Tj
0.856 0 Td
(would)Tj
2.7156 0 Td
(also)Tj
-35.9487 -1.2983 Td
(be)Tj
1.1508 0 Td
(beneficial)Tj
4.0479 0 Td
(to)Tj
1.0261 0 Td
(replace)Tj
3.0557 0 Td
(ivermectin)Tj
4.5184 0 Td
(in)Tj
1.0375 0 Td
(significant)Tj
4.388 0 Td
(portions)Tj
3.5943 0 Td
(of)Tj
1.0148 0 Td
(West)Tj
2.2734 0 Td
(Africa)Tj
2.6872 0 Td
(that)Tj
1.7745 0 Td
(are)Tj
1.4513 0 Td
(co-endemic)Tj
-32.0199 -1.2982 Td
(for)Tj
1.3832 0 Td
(onchocerciasis)Tj
6.0662 0 Td
(and)Tj
1.7291 0 Td
(a)Tj
0.6576 0 Td
(third)Tj
2.211 0 Td
(filarial)Tj
2.7723 0 Td
(disease,)Tj
3.2428 0 Td
(loiasis)Tj
2.6645 0 Td
(\(caused)Tj
3.2599 0 Td
(by)Tj
1.1792 0 Td
(infection)Tj
3.7927 0 Td
(with)Tj
/F10 1 Tf
1.9956 0 Td
()Tj
1.7008 0 Td
()Tj
/F9 1 Tf
1.4173 0 Td
(worms\).)Tj
-34.0722 -1.304 Td
(Loiasis)Tj
2.9536 0 Td
(typically)Tj
3.5603 0 Td
(creates)Tj
2.9594 0 Td
(a)Tj
0.6519 0 Td
(high)Tj
2.007 0 Td
(burden)Tj
3.1237 0 Td
(of)Tj
1.0148 0 Td
(circulating)Tj
4.4957 0 Td
(mf;)Tj
1.5534 0 Td
(treatment)Tj
4.1329 0 Td
(of)Tj
1.0148 0 Td
(co-infected)Tj
4.7055 0 Td
(individuals)Tj
-32.173 -1.2982 Td
(with)Tj
1.9955 0 Td
(ivermectin)Tj
4.5184 0 Td
(carries)Tj
2.8687 0 Td
(the)Tj
1.474 0 Td
(risk)Tj
1.7121 0 Td
(of)Tj
1.0148 0 Td
(severe)Tj
2.6815 0 Td
(adverse)Tj
3.2145 0 Td
(effects)Tj
2.7269 0 Td
(or)Tj
1.0942 0 Td
(death)Tj
2.4321 0 Td
([)Tj
0.83 0.64 0.02 0 k
(6)Tj
0 g
(].)Tj
1.6044 0 Td
(An)Tj
1.4513 0 Td
(agent)Tj
2.3868 0 Td
(that)Tj
1.7801 0 Td
(selectively)Tj
-32.9553 -1.2983 Td
(targets)Tj
2.8686 0 Td
(adult)Tj
2.2564 0 Td
(worms)Tj
2.965 0 Td
(without)Tj
3.3278 0 Td
(acutely)Tj
3.0274 0 Td
(affecting)Tj
3.6567 0 Td
(mf)Tj
1.3266 0 Td
(would)Tj
2.7156 0 Td
(transform)Tj
4.2179 0 Td
(the)Tj
1.4683 0 Td
(treatment)Tj
4.1386 0 Td
(of)Tj
1.0148 0 Td
(these)Tj
2.2507 0 Td
(debil-)Tj
-35.2344 -1.3039 Td
(itating)Tj
2.7949 0 Td
(diseases.)Tj
-1.5987 -1.2983 Td
(Filarial)Tj
3.016 0 Td
(worms)Tj
2.965 0 Td
(causing)Tj
3.2428 0 Td
(onchocerciasis)Tj
6.0661 0 Td
(and)Tj
1.7292 0 Td
(LF)Tj
1.2869 0 Td
(carry)Tj
2.279 0 Td
(an)Tj
1.2019 0 Td
(obligate)Tj
3.3676 0 Td
(symbiotic)Tj
4.1215 0 Td
(bacterium,)Tj
/F10 1 Tf
4.5184 0 Td
()Tj
-34.9906 -1.2982 Td
()Tj
/F9 1 Tf
(,)Tj
3.05 0 Td
(which)Tj
2.6476 0 Td
(is)Tj
0.8447 0 Td
(essential)Tj
3.5829 0 Td
(for)Tj
1.3833 0 Td
(worm)Tj
2.6022 0 Td
(fertility)Tj
3.1295 0 Td
(and)Tj
1.7291 0 Td
(ultimate)Tj
3.5319 0 Td
(survival.)Tj
3.5603 0 Td
(Clinical)Tj
3.3165 0 Td
(studies)Tj
2.9821 0 Td
(have)Tj
2.0579 0 Td
(demon-)Tj
-34.418 -1.2983 Td
(strated)Tj
2.931 0 Td
(effective)Tj
3.5092 0 Td
(treatment)Tj
4.1386 0 Td
(of)Tj
1.0148 0 Td
(these)Tj
2.2563 0 Td
(diseases)Tj
3.3789 0 Td
(through)Tj
3.4413 0 Td
(depletion)Tj
3.9798 0 Td
(of)Tj
/F10 1 Tf
1.0148 0 Td
()Tj
/F9 1 Tf
4.4844 0 Td
(by)Tj
1.1792 0 Td
(anti-bacterial)Tj
-31.3283 -1.3039 Td
(therapy)Tj
3.2484 0 Td
(with)Tj
1.9956 0 Td
(doxycycline)Tj
4.9606 0 Td
([)Tj
0.83 0.64 0.02 0 k
(7)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(].)Tj
2.3017 0 Td
(Of)Tj
1.2529 0 Td
(note,)Tj
2.2224 0 Td
(this)Tj
1.6781 0 Td
(mechanism)Tj
4.8415 0 Td
(has)Tj
1.5421 0 Td
(three)Tj
2.2677 0 Td
(distinct)Tj
3.2088 0 Td
(elements)Tj
3.7643 0 Td
(that)Tj
1.7802 0 Td
(are)Tj
-35.0643 -1.2983 Td
(considered)Tj
4.5977 0 Td
(particularly)Tj
4.8132 0 Td
(desirable)Tj
3.7814 0 Td
(for)Tj
1.389 0 Td
(a)Tj
0.6519 0 Td
(new)Tj
1.8766 0 Td
(anti-filarial)Tj
4.6714 0 Td
(agent:)Tj
-21.7812 -1.8992 Td
(1.)Tj
1.2018 0 Td
(It)Tj
0.8561 0 Td
(sterilizes)Tj
3.651 0 Td
(adult)Tj
2.2564 0 Td
(worms)Tj
2.9593 0 Td
(rather)Tj
2.6475 0 Td
(than)Tj
2.0296 0 Td
(directly)Tj
3.2315 0 Td
(killing)Tj
2.7609 0 Td
(mf.)Tj
1.5478 0 Td
(Interrupting)Tj
5.1987 0 Td
(the)Tj
1.474 0 Td
(production)Tj
4.7111 0 Td
(of)Tj
1.0148 0 Td
(mf)Tj
-34.3387 -1.3039 Td
(results)Tj
2.8063 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4683 0 Td
(slow)Tj
2.0183 0 Td
(decline)Tj
3.0784 0 Td
(of)Tj
1.0148 0 Td
(circulating)Tj
4.4957 0 Td
(mf)Tj
1.3266 0 Td
(levels.)Tj
-18.4477 -1.8992 Td
(2.)Tj
1.2018 0 Td
(Adult)Tj
2.5002 0 Td
(worm)Tj
2.6022 0 Td
(death)Tj
2.4321 0 Td
(occurs)Tj
2.8346 0 Td
(slowly.)Tj
2.9423 0 Td
(After)Tj
2.2904 0 Td
(depletion)Tj
3.9742 0 Td
(of)Tj
/F10 1 Tf
1.0148 0 Td
()Tj
/F9 1 Tf
(,)Tj
4.7111 0 Td
(adult)Tj
2.2564 0 Td
(worms)Tj
2.9593 0 Td
(are)Tj
1.4514 0 Td
(committed)Tj
-31.969 -1.2983 Td
(to)Tj
1.0205 0 Td
(death,)Tj
2.6589 0 Td
(but)Tj
1.5534 0 Td
(take)Tj
1.8708 0 Td
(months)Tj
3.2825 0 Td
(to)Tj
1.0261 0 Td
(be)Tj
1.1509 0 Td
(fully)Tj
1.9842 0 Td
(cleared)Tj
3.0671 0 Td
(from)Tj
2.2053 0 Td
(the)Tj
1.4741 0 Td
(host.)Tj
ET
Q
q
1 j
1 J
0.0001 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.26 183.288 23.6976 re
W* n
q
183.288 0 0 23.6976 36 741.26 cm
q
/I2 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0.0001 w
7.9999 0 0 7.9999 490.167 745.795 cm
BT
/F0 1 Tf
-0.005 Tc
1 TL
0 0 Td
(Discover)Tj
3.8197 0 Td
(y)Tj
0.7157 0 Td
(of)Tj
1.0418 0 Td
(ABBV-4)Tj
3.5079 0 Td
(083)Tj
ET
Q
q
1 j
1 J
0.0001 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
163.559 34.9228 m
317.707 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
-0.005 Tc
1 TL
0 0 Td
(PLOS)Tj
2.8559 0 Td
(Neglected)Tj
4.6417 0 Td
(Tropical)Tj
3.7135 0 Td
(Disease)Tj
3.5433 0 Td
(s)Tj
0.7158 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8197 0 Td
(1/journal.pn)Tj
5.1237 0 Td
(td.00071)Tj
3.8197 0 Td
(59)Tj
0 g
2.0905 0 Td
(February)Tj
4.1599 0 Td
(28,)Tj
1.5874 0 Td
(2019)Tj
23.1805 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(13)Tj
/F12 1 Tf
-0.025 Tc
-66.402 84.0904 Td
(SAW\))Tj
2.3811 0 Td
(is)Tj
0.8362 0 Td
(supported)Tj
3.9969 0 Td
(by)Tj
1.1126 0 Td
(a)Tj
0.6378 0 Td
(grant)Tj
2.1543 0 Td
(from)Tj
2.0056 0 Td
(BMGF)Tj
2.5086 0 Td
(awarded)Tj
-15.6331 -1.3748 Td
(to)Tj
0.9496 0 Td
(the)Tj
1.3677 0 Td
(Liverpool)Tj
3.6496 0 Td
(School)Tj
2.7851 0 Td
(of)Tj
0.9425 0 Td
(Tropical)Tj
3.1819 0 Td
(Medicine)Tj
-12.8764 -1.3749 Td
(\(OPP105432)Tj
4.7835 0 Td
(4\).)Tj
1.2259 0 Td
(AbbVie)Tj
2.8347 0 Td
(supporte)Tj
3.2953 0 Td
(d)Tj
0.6945 0 Td
(TWvG,)Tj
2.7355 0 Td
(HM,)Tj
-15.5694 -1.3748 Td
(RFC,)Tj
1.9771 0 Td
(BSB,)Tj
2.0197 0 Td
(RC,)Tj
1.5591 0 Td
(DS,)Tj
1.5591 0 Td
(JM,)Tj
1.6157 0 Td
(MR,)Tj
1.7859 0 Td
(KM,)Tj
1.722 0 Td
(and)Tj
1.5874 0 Td
(DJK.)Tj
1.9843 0 Td
(TWvG)Tj
-15.8103 -1.3748 Td
(received)Tj
3.3023 0 Td
(additional)Tj
3.7914 0 Td
(support)Tj
3.0969 0 Td
(from)Tj
2.0126 0 Td
(the)Tj
1.3677 0 Td
(Franciscan)Tj
-13.5709 -1.3748 Td
(Institute)Tj
3.2244 0 Td
(for)Tj
1.2543 0 Td
(World)Tj
2.4733 0 Td
(Health.)Tj
2.7992 0 Td
(The)Tj
1.5874 0 Td
(funders)Tj
3.0473 0 Td
(had)Tj
1.5874 0 Td
(no)Tj
1.1622 0 Td
(role)Tj
-17.1355 -1.3748 Td
(in)Tj
0.8858 0 Td
(study)Tj
2.2677 0 Td
(design,)Tj
2.8985 0 Td
(data)Tj
1.7929 0 Td
(collection)Tj
3.7347 0 Td
(and)Tj
1.5945 0 Td
(analysis)Tj
2.9622 0 Td
(,)Tj
-16.1363 -1.3748 Td
(decision)Tj
3.2882 0 Td
(to)Tj
0.9496 0 Td
(publish,)Tj
3.1465 0 Td
(or)Tj
0.9992 0 Td
(preparation)Tj
4.4433 0 Td
(of)Tj
0.9496 0 Td
(the)Tj
-13.7764 -1.3748 Td
(manuscript.)Tj
/F11 1 Tf
0 -2.126 Td
(Competing)Tj
4.3795 0 Td
(interests)Tj
3.3307 0 Td
(:)Tj
/F12 1 Tf
0.4819 0 Td
(Competi)Tj
3.0898 0 Td
(ng)Tj
1.1693 0 Td
(interests:)Tj
3.6142 0 Td
(TWvG)Tj
-16.0654 -1.3749 Td
(is)Tj
0.8362 0 Td
(a)Tj
0.6378 0 Td
(paid)Tj
1.7858 0 Td
(consultant)Tj
4.0819 0 Td
(to)Tj
0.9426 0 Td
(DNDi)Tj
2.1827 0 Td
(and)Tj
1.5874 0 Td
(has)Tj
1.5307 0 Td
(advised)Tj
3.0473 0 Td
(on)Tj
-16.6324 -1.3748 Td
(their)Tj
1.8708 0 Td
(helminth)Tj
3.4583 0 Td
(programs)Tj
3.6284 0 Td
(.)Tj
0.4465 0 Td
(DJK)Tj
1.7504 0 Td
(is)Tj
0.8362 0 Td
(an)Tj
1.1197 0 Td
(unpaid)Tj
-13.1103 -1.3748 Td
(consultant)Tj
4.0819 0 Td
(to)Tj
0.9496 0 Td
(DNDi.)Tj
2.4024 0 Td
(DJK)Tj
1.7504 0 Td
(KM,)Tj
1.722 0 Td
(MJT,)Tj
2.0977 0 Td
(MPH,)Tj
2.3102 0 Td
(JDT)Tj
1.7008 0 Td
(and)Tj
-17.015 -1.3748 Td
(SAW)Tj
2.0763 0 Td
(are)Tj
1.3678 0 Td
(non-paid)Tj
3.5079 0 Td
(members)Tj
3.7772 0 Td
(of)Tj
0.9496 0 Td
(the)Tj
1.3677 0 Td
(MacroDA)Tj
-13.0465 -1.3748 Td
(consortium)Tj
4.2449 0 Td
(.)Tj
0.4464 0 Td
(TWvG)Tj
2.5087 0 Td
(has)Tj
1.5378 0 Td
(been)Tj
2.0055 0 Td
(a)Tj
0.6449 0 Td
(non-paid)Tj
3.5079 0 Td
(member)Tj
3.352 0 Td
(of)Tj
-18.2481 -1.3748 Td
(the)Tj
1.3677 0 Td
(External)Tj
3.189 0 Td
(Scientific)Tj
3.5717 0 Td
(Advisory)Tj
3.4583 0 Td
(Committe)Tj
3.6283 0 Td
(e)Tj
0.6449 0 Td
(\(ESAC\))Tj
-15.8599 -1.3748 Td
(for)Tj
1.2543 0 Td
(the)Tj
1.3748 0 Td
(Anti-Wolba)Tj
4.1174 0 Td
(chia)Tj
1.7291 0 Td
(Consortium)Tj
4.5709 0 Td
(\(A)Tj
ET
Q
q
1 j
1 J
0.0001 w
5.5998 0 0 5.5998 147.061 529.625 cm
BT
/F15 1 Tf
1 TL
0 0 Td
()Tj
ET
Q
q
1 j
1 J
0.0001 w
7.9999 0 0 7.9999 150.35 526.734 cm
BT
/F12 1 Tf
-0.025 Tc
1 TL
0 0 Td
(WOL\).)Tj
2.6149 0 Td
(RFK,)Tj
-16.9087 -1.3748 Td
(BSB,)Tj
2.0197 0 Td
(RC,)Tj
1.5591 0 Td
(DS,)Tj
1.5591 0 Td
(JM,)Tj
1.6157 0 Td
(MR,)Tj
1.7859 0 Td
(KM,)Tj
1.722 0 Td
(and)Tj
1.5874 0 Td
(DJK)Tj
1.7575 0 Td
(are)Tj
-13.6064 -1.3748 Td
(employees)Tj
4.2237 0 Td
(of)Tj
0.9496 0 Td
(AbbVie.)Tj
3.0544 0 Td
(HM)Tj
1.559 0 Td
(is)Tj
0.8363 0 Td
(a)Tj
0.6378 0 Td
(paid)Tj
1.7858 0 Td
(consultant)Tj
4.0818 0 Td
(to)Tj
-17.1284 -1.3748 Td
(AbbVie.)Tj
3.0544 0 Td
(TWvG)Tj
2.5087 0 Td
(is)Tj
0.8362 0 Td
(an)Tj
1.1126 0 Td
(employee)Tj
3.7985 0 Td
(of)Tj
0.9496 0 Td
(Franciscan)Tj
-12.26 -1.3748 Td
(University)Tj
3.6922 0 Td
(,)Tj
0.4465 0 Td
(acting)Tj
2.459 0 Td
(as)Tj
1.063 0 Td
(an)Tj
1.1126 0 Td
(unpaid)Tj
2.7284 0 Td
(consultant)Tj
4.0818 0 Td
(to)Tj
-15.5835 -1.3748 Td
(AbbVie.)Tj
3.0544 0 Td
(The)Tj
1.5874 0 Td
(other)Tj
2.1544 0 Td
(authors)Tj
3.0472 0 Td
(declare)Tj
2.8772 0 Td
(no)Tj
1.1693 0 Td
(competing)Tj
-13.8899 -1.3748 Td
(interests.)Tj
3.6142 0 Td
(TWvG,)Tj
2.7355 0 Td
(DJK,)Tj
1.9772 0 Td
(and)Tj
1.5874 0 Td
(KCM)Tj
2.0268 0 Td
(are)Tj
1.3677 0 Td
(inventors)Tj
3.6566 0 Td
(on)Tj
-16.9654 -1.3748 Td
(patent/pate)Tj
4.1245 0 Td
(nt)Tj
0.9496 0 Td
(application)Tj
4.2166 0 Td
(EP3116888)Tj
4.3087 0 Td
(A1)Tj
1.2188 0 Td
(\(4"-O-)Tj
-14.8182 -1.3819 Td
(substituted)Tj
4.3371 0 Td
(Tylosin)Tj
2.8701 0 Td
(A)Tj
0.7441 0 Td
(Derivatives)Tj
4.4221 0 Td
(\))Tj
0.5315 0 Td
(held)Tj
1.7786 0 Td
(by)Tj
1.1126 0 Td
(AbbVie)Tj
-15.7961 -1.3749 Td
(that)Tj
1.6229 0 Td
(covers)Tj
2.6858 0 Td
(4"-0-substitut)Tj
5.0103 0 Td
(ed)Tj
1.1126 0 Td
(tylosin)Tj
2.6575 0 Td
(a)Tj
0.6378 0 Td
(derivatives.)Tj
-13.7269 -1.3748 Td
(TWvG,)Tj
2.7355 0 Td
(DJK,)Tj
1.9772 0 Td
(and)Tj
1.5874 0 Td
(KCM)Tj
2.0268 0 Td
(are)Tj
1.3677 0 Td
(inventors)Tj
3.6567 0 Td
(on)Tj
1.1692 0 Td
(patent/)Tj
-14.5205 -1.3748 Td
(patent)Tj
2.5229 0 Td
(applicati)Tj
3.0402 0 Td
(on)Tj
1.1693 0 Td
(US201502593)Tj
5.3717 0 Td
(74/US10072040)Tj
-12.1041 -1.3748 Td
(\(Tylosin)Tj
3.5363 0 Td
(A)Tj
0.7441 0 Td
(Analogs)Tj
3.2032 0 Td
(and)Tj
1.5874 0 Td
(Derivatives)Tj
4.4221 0 Td
(\))Tj
0.5315 0 Td
(held)Tj
1.7786 0 Td
(by)Tj
-15.8032 -1.3748 Td
(AbbVie)Tj
2.8347 0 Td
(that)Tj
1.6229 0 Td
(covers)Tj
2.6858 0 Td
(Tylosin)Tj
2.8701 0 Td
(a)Tj
0.6449 0 Td
(analogs)Tj
3.0969 0 Td
(and)Tj
-13.7553 -1.3748 Td
(derivatives.)Tj
4.3938 0 Td
(TWvG,)Tj
2.7354 0 Td
(DJK,)Tj
1.9772 0 Td
(and)Tj
1.5874 0 Td
(KCM)Tj
2.0268 0 Td
(are)Tj
1.3677 0 Td
(inventors)Tj
3.6637 0 Td
(on)Tj
-17.752 -1.3748 Td
(patent/pate)Tj
4.1245 0 Td
(nt)Tj
0.9496 0 Td
(application)Tj
4.2166 0 Td
(US2016020)Tj
4.422 0 Td
(0757)Tj
-13.7127 -1.3749 Td
(\(Tylosin)Tj
3.5363 0 Td
(A)Tj
0.7441 0 Td
(Analogs)Tj
3.2032 0 Td
(and)Tj
1.5874 0 Td
(Derivatives)Tj
4.4221 0 Td
(\))Tj
0.5315 0 Td
(held)Tj
1.7786 0 Td
(by)Tj
-15.8032 -1.3748 Td
(AbbVie)Tj
2.8347 0 Td
(that)Tj
1.6229 0 Td
(covers)Tj
2.6858 0 Td
(Tylosin)Tj
2.8701 0 Td
(a)Tj
0.6449 0 Td
(analogs)Tj
3.0969 0 Td
(and)Tj
-13.7553 -1.3748 Td
(derivatives.)Tj
4.3938 0 Td
(TWvG,)Tj
2.7354 0 Td
(DJK,)Tj
1.9772 0 Td
(and)Tj
1.5874 0 Td
(KCM,)Tj
2.2465 0 Td
(MJT,)Tj
2.0976 0 Td
(SAW,)Tj
2.296 0 Td
(LF,)Tj
-17.3339 -1.3748 Td
(and)Tj
1.5875 0 Td
(JT)Tj
1.1126 0 Td
(are)Tj
1.3748 0 Td
(inventors)Tj
3.6567 0 Td
(on)Tj
1.1693 0 Td
(patent/pate)Tj
4.1244 0 Td
(nt)Tj
0.9496 0 Td
(application)Tj
-13.9749 -1.3748 Td
(US20170368)Tj
4.8969 0 Td
(088)Tj
1.6441 0 Td
(\(Treatment)Tj
4.6701 0 Td
(of)Tj
0.9497 0 Td
(Filarial)Tj
2.5652 0 Td
(Diseases)Tj
3.6638 0 Td
(\))Tj
-18.3898 -1.3748 Td
(held)Tj
1.7788 0 Td
(by)Tj
1.1197 0 Td
(AbbVie)Tj
2.8276 0 Td
(that)Tj
1.6299 0 Td
(covers)Tj
2.6858 0 Td
(Treatment)Tj
4.004 0 Td
(of)Tj
0.9495 0 Td
(Filarial)Tj
-14.9953 -1.3748 Td
(Diseases.)Tj
3.756 0 Td
(TWvG,)Tj
2.7283 0 Td
(DJK,)Tj
1.9772 0 Td
(and)Tj
1.5945 0 Td
(KCM,)Tj
2.2465 0 Td
(MJT,)Tj
2.0905 0 Td
(SAW,)Tj
2.3031 0 Td
(LF,)Tj
-16.6961 -1.3749 Td
(and)Tj
1.5875 0 Td
(JT)Tj
1.1126 0 Td
(are)Tj
1.3748 0 Td
(inventors)Tj
3.6567 0 Td
(on)Tj
1.1693 0 Td
(patent/pate)Tj
4.1244 0 Td
(nt)Tj
0.9496 0 Td
(application)Tj
-13.9749 -1.3748 Td
(EP3242662A1-)Tj
5.6198 0 Td
(A4)Tj
1.2189 0 Td
(\(Treatm)Tj
3.2953 0 Td
(ent)Tj
1.3748 0 Td
(of)Tj
0.9496 0 Td
(Filarial)Tj
-12.4584 -1.3748 Td
(Diseases\))Tj
4.1953 0 Td
(held)Tj
1.7788 0 Td
(by)Tj
1.1197 0 Td
(AbbVie)Tj
2.8276 0 Td
(that)Tj
1.6299 0 Td
(covers)Tj
2.6859 0 Td
(Treatment)Tj
4.0038 0 Td
(of)Tj
-18.241 -1.3748 Td
(Filarial)Tj
2.5654 0 Td
(Diseases.)Tj
3.7489 0 Td
(This)Tj
1.7858 0 Td
(study)Tj
2.2606 0 Td
(was)Tj
1.7079 0 Td
(performe)Tj
3.4086 0 Td
(d)Tj
0.6945 0 Td
(under)Tj
2.3741 0 Td
(a)Tj
-18.5458 -1.3748 Td
(partnership)Tj
4.4434 0 Td
(agreement)Tj
4.1669 0 Td
(between)Tj
3.3237 0 Td
(AbbVie)Tj
2.8346 0 Td
(and)Tj
1.5874 0 Td
(the)Tj
-16.356 -1.3748 Td
(Liverpool)Tj
3.6497 0 Td
(School)Tj
2.7779 0 Td
(of)Tj
0.9497 0 Td
(Tropical)Tj
3.1748 0 Td
(Medicine,)Tj
3.7983 0 Td
(which)Tj
2.4237 0 Td
(has)Tj
-16.7741 -1.3748 Td
(confident)Tj
3.4371 0 Td
(iality)Tj
1.8992 0 Td
(provisions.)Tj
4.2945 0 Td
(Compounds)Tj
4.7622 0 Td
(were)Tj
-14.393 -1.3749 Td
(provided)Tj
3.4583 0 Td
(to)Tj
0.9496 0 Td
(the)Tj
1.3678 0 Td
(University)Tj
3.9189 0 Td
(of)Tj
0.9425 0 Td
(Bonn)Tj
2.1685 0 Td
(through)Tj
3.1464 0 Td
(the)Tj
-15.952 -1.3748 Td
(Anti-Wolbac)Tj
4.5426 0 Td
(hia)Tj
1.311 0 Td
(Consorti)Tj
3.1182 0 Td
(um)Tj
1.4456 0 Td
(\(A)Tj
ET
Q
q
1 j
1 J
0.0001 w
5.5998 0 0 5.5998 126.028 188.617 cm
BT
/F15 1 Tf
1 TL
0 0 Td
()Tj
ET
Q
q
1 j
1 J
0.0001 w
7.9999 0 0 7.9999 129.316 185.726 cm
BT
/F12 1 Tf
-0.025 Tc
1 TL
0 0 Td
(WOL\).)Tj
2.6149 0 Td
(ABBV-4083)Tj
-14.2795 -1.3748 Td
(and)Tj
1.5874 0 Td
(related)Tj
2.7142 0 Td
(compounds)Tj
4.6559 0 Td
(are)Tj
1.3749 0 Td
(available)Tj
3.3802 0 Td
(from)Tj
2.0055 0 Td
(AbbVie)Tj
-15.7181 -1.3748 Td
(under)Tj
2.3669 0 Td
(a)Tj
0.6449 0 Td
(material)Tj
3.189 0 Td
(transfer)Tj
3.0827 0 Td
(agreement)Tj
3.9472 0 Td
(.)Tj
ET
Q
endstream
endobj
28 0 obj
<>
endobj
29 0 obj
<>/XObject<>>>
endobj
30 0 obj
[34 0 R 35 0 R 36 0 R 37 0 R 38 0 R 39 0 R 40 0 R 41 0 R 42 0 R 43 0 R]
endobj
34 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref009)>>
endobj
35 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref008)>>
endobj
36 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref010)>>
endobj
37 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.g001)>>
endobj
38 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref011)>>
endobj
39 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref012)>>
endobj
40 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref013)>>
endobj
41 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.t001)>>
endobj
42 0 obj
<>/Border[0 0 0]/Dest(Rpntd.0007159.ref014)>>
endobj
43 0 obj
<>/Border[0 0 0]/A 44 0 R>>
endobj
44 0 obj
<>
endobj
31 0 obj
<>stream
q
Q
q
12.0189 54.5953 583.087 707.414 re
W* n
q
1 0 0 1 12.0189 54.5953 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
0.83 0.64 0.02 0 k
379.332 693.298 m
384.094 693.298 l
h
f*
507.061 609.335 m
511.767 609.335 l
h
f*
325.701 544.309 m
335.112 544.309 l
h
f*
549.468 295.03 m
568.403 295.03 l
h
f*
382.45 269.065 m
391.635 269.065 l
h
f*
425.31 256.082 m
434.494 256.082 l
h
f*
498.614 230.06 m
507.798 230.06 l
h
f*
203.414 152.05 m
232.554 152.05 l
h
f*
523.843 81.9213 m
533.254 81.9213 l
h
f*
0 g
1 j
1 J
0.0001 w
10 0 0 10 200.012 707.414 cm
BT
/F9 1 Tf
-0.004 Tc
1 TL
0 0 Td
(3.)Tj
1.2018 0 Td
(Microfilaria)Tj
4.989 0 Td
(depleted)Tj
3.6056 0 Td
(of)Tj
1.0148 0 Td
(Wolbachia)Tj
4.5298 0 Td
(are)Tj
1.4513 0 Td
(less)Tj
1.6101 0 Td
(able)Tj
1.8311 0 Td
(to)Tj
1.0262 0 Td
(develop)Tj
3.3221 0 Td
(in)Tj
1.0318 0 Td
(the)Tj
1.4684 0 Td
(intermediate)Tj
5.3234 0 Td
(vector,)Tj
2.9254 0 Td
(and)Tj
-34.129 -1.3039 Td
(thus)Tj
1.9332 0 Td
(less)Tj
1.6101 0 Td
(competent)Tj
4.4787 0 Td
(to)Tj
1.0262 0 Td
(spread)Tj
2.8573 0 Td
(the)Tj
1.4683 0 Td
(disease)Tj
3.0161 0 Td
([)Tj
0.83 0.64 0.02 0 k
(9)Tj
0 g
(])Tj
-16.3955 -1.8992 Td
(Since)Tj
2.3584 0 Td
(the)Tj
1.474 0 Td
(pathologies)Tj
4.7735 0 Td
(of)Tj
1.0148 0 Td
(both)Tj
2.0579 0 Td
(diseases)Tj
3.3789 0 Td
(have)Tj
2.0579 0 Td
(been)Tj
2.126 0 Td
(associated)Tj
4.2576 0 Td
(with)Tj
/F10 1 Tf
1.9956 0 Td
()Tj
/F9 1 Tf
4.4844 0 Td
(release,)Tj
3.1294 0 Td
(an)Tj
-34.3046 -1.2982 Td
(agent)Tj
2.3867 0 Td
(that)Tj
1.7802 0 Td
(acts)Tj
1.7347 0 Td
(by)Tj
1.1849 0 Td
(reducing)Tj
/F10 1 Tf
3.7757 0 Td
()Tj
/F9 1 Tf
4.4844 0 Td
(populations)Tj
4.9493 0 Td
(within)Tj
2.8119 0 Td
(the)Tj
1.4684 0 Td
(adult)Tj
2.2563 0 Td
(worm)Tj
2.6022 0 Td
(may)Tj
1.9276 0 Td
(have)Tj
2.0579 0 Td
(additional)Tj
-33.4202 -1.2983 Td
(immunological)Tj
6.2985 0 Td
(benefits)Tj
3.3335 0 Td
(over)Tj
1.9786 0 Td
(agents)Tj
2.7496 0 Td
(that)Tj
1.7801 0 Td
(are)Tj
1.4457 0 Td
(directly)Tj
3.2371 0 Td
(macrofilaricidal.)Tj
6.7691 0 Td
(A)Tj
0.9071 0 Td
(slow-kill)Tj
3.6227 0 Td
(mode)Tj
2.5001 0 Td
(of)Tj
-34.6221 -1.3039 Td
(action)Tj
2.6985 0 Td
(reduces)Tj
3.2768 0 Td
(the)Tj
1.4684 0 Td
(probability)Tj
4.5977 0 Td
(of)Tj
1.0148 0 Td
(adverse)Tj
3.2145 0 Td
(reactions)Tj
3.8551 0 Td
(related)Tj
2.948 0 Td
(to)Tj
1.0205 0 Td
(sudden)Tj
3.1408 0 Td
(worm)Tj
2.6021 0 Td
(death.)Tj
-28.641 -1.2983 Td
(T)Tj
-0.01 Tc
(he)Tj
1.7744 0 Td
(concept)Tj
3.3166 0 Td
(of)Tj
1.0034 0 Td
(targeting)Tj
/F10 1 Tf
3.7417 0 Td
()Tj
/F9 1 Tf
4.4277 0 Td
(as)Tj
1.0035 0 Td
(an)Tj
1.1905 0 Td
(approach)Tj
3.9061 0 Td
(to)Tj
1.0092 0 Td
(treating)Tj
3.2825 0 Td
(filarial)Tj
2.7212 0 Td
(disease)Tj
2.9764 0 Td
(has)Tj
1.525 0 Td
(been)Tj
2.0976 0 Td
(clini-)Tj
-35.172 -1.2982 Td
(cally)Tj
1.9955 0 Td
(validated)Tj
3.7758 0 Td
(using)Tj
2.364 0 Td
(the)Tj
1.4514 0 Td
(tetracycline)Tj
4.7565 0 Td
(antibiotics)Tj
4.3369 0 Td
(doxycycline)Tj
4.8926 0 Td
(and)Tj
1.7121 0 Td
(minocycline)Tj
5.0854 0 Td
([)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(];)Tj
1.576 0 Td
(however)Tj
3.5716 0 Td
(these)Tj
-35.5178 -1.304 Td
(drugs)Tj
2.4434 0 Td
(are)Tj
1.4287 0 Td
(not)Tj
1.559 0 Td
(ideal)Tj
2.0863 0 Td
(for)Tj
1.3663 0 Td
(use)Tj
1.5137 0 Td
(in)Tj
1.0261 0 Td
(the)Tj
1.4513 0 Td
(field,)Tj
2.16 0 Td
(as)Tj
1.0035 0 Td
(they)Tj
1.9048 0 Td
(are)Tj
1.4287 0 Td
(contraindicated)Tj
6.4289 0 Td
(in)Tj
1.0262 0 Td
(children)Tj
3.5092 0 Td
(and)Tj
1.7122 0 Td
(in)Tj
1.0204 0 Td
(women)Tj
3.1748 0 Td
(of)Tj
-36.2435 -1.2982 Td
(child-bearing)Tj
5.4991 0 Td
(age.)Tj
1.7462 0 Td
(The)Tj
1.7631 0 Td
(long-term)Tj
4.1952 0 Td
(goal)Tj
1.8482 0 Td
(of)Tj
1.0035 0 Td
(the)Tj
1.4513 0 Td
(Anti-)Tj
/F10 1 Tf
()Tj
/F9 1 Tf
6.548 0 Td
(\(A)Tj
/F15 1 Tf
0 Tc
()Tj
/F9 1 Tf
-0.01 Tc
(WOL\))Tj
4.0705 0 Td
(Consortium)Tj
5.0343 0 Td
(is)Tj
0.8334 0 Td
(the)Tj
1.4513 0 Td
(dis-)Tj
-35.4441 -1.2983 Td
(covery)Tj
2.8176 0 Td
(and)Tj
1.7121 0 Td
(development)Tj
5.3461 0 Td
(of)Tj
1.0035 0 Td
(novel)Tj
2.3697 0 Td
(anti-)Tj
/F10 1 Tf
()Tj
/F9 1 Tf
6.2985 0 Td
(agents)Tj
2.7156 0 Td
(with)Tj
1.9729 0 Td
(superior)Tj
3.515 0 Td
(profiles.)Tj
3.3732 0 Td
(Recently)Tj
3.6113 0 Td
(we)Tj
-34.7355 -1.2983 Td
(reported)Tj
3.6113 0 Td
(the)Tj
1.4513 0 Td
(discovery)Tj
3.9571 0 Td
(of)Tj
1.0035 0 Td
(a)Tj
0.6463 0 Td
(new)Tj
1.8595 0 Td
(anti-)Tj
/F10 1 Tf
()Tj
/F9 1 Tf
6.2985 0 Td
(compound,)Tj
4.7679 0 Td
(ABBV-4083,)Tj
5.176 0 Td
(derived)Tj
3.1748 0 Td
(from)Tj
2.1827 0 Td
(the)Tj
-34.1289 -1.3039 Td
(macrolide)Tj
4.1839 0 Td
(antibiotic)Tj
3.9798 0 Td
(Tylosin)Tj
3.1748 0 Td
(A)Tj
0.8957 0 Td
([)Tj
0.83 0.64 0.02 0 k
(10)Tj
0 g
(].)Tj
2.0466 0 Td
(ABBV-4083)Tj
4.9606 0 Td
(exceeds)Tj
3.2258 0 Td
(the)Tj
1.4513 0 Td
(efficacy)Tj
3.1748 0 Td
(of)Tj
1.0035 0 Td
(doxycycline)Tj
4.8925 0 Td
(and)Tj
1.7122 0 Td
(meets)Tj
-34.7015 -1.2982 Td
(many)Tj
2.4491 0 Td
(of)Tj
1.0034 0 Td
(the)Tj
1.4514 0 Td
(stated)Tj
2.5284 0 Td
(pre-clinical)Tj
4.6658 0 Td
(goals)Tj
2.2054 0 Td
(for)Tj
1.3663 0 Td
(a)Tj
0.6519 0 Td
(next-generation)Tj
6.5027 0 Td
(anti-filarial)Tj
4.5921 0 Td
(agent.)Tj
2.5795 0 Td
(Herein)Tj
2.9877 0 Td
(we)Tj
1.3152 0 Td
(describe)Tj
-34.2989 -1.2983 Td
(the)Tj
1.4513 0 Td
(details)Tj
2.7326 0 Td
(of)Tj
1.0034 0 Td
(the)Tj
1.4513 0 Td
(discovery)Tj
3.9572 0 Td
(program)Tj
3.668 0 Td
(leading)Tj
3.0897 0 Td
(to)Tj
1.0092 0 Td
(the)Tj
1.4513 0 Td
(identification)Tj
5.5048 0 Td
(of)Tj
1.0035 0 Td
(this)Tj
1.6498 0 Td
(novel)Tj
2.3697 0 Td
(anti-filarial)Tj
4.5921 0 Td
(agent.)Tj
ET
Q
q
1 j
1 J
0.0001 w
11.9999 0 0 11.9999 200.012 492.264 cm
BT
/F3 1 Tf
-0.0033 Tc
1 TL
0 0 Td
(Methods)Tj
/F16 1 Tf
0 -1.4976 Td
(Ethics)Tj
2.7779 0 Td
(statement)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 200.012 457.285 cm
BT
/F9 1 Tf
-0.004 Tc
1 TL
0 0 Td
(Animal)Tj
3.2201 0 Td
(experiments)Tj
5.1363 0 Td
(using)Tj
/F10 1 Tf
2.3925 0 Td
()Tj
5.3347 0 Td
( )Tj
/F9 1 Tf
4.8869 0 Td
(were)Tj
2.126 0 Td
(performed)Tj
4.4674 0 Td
(at)Tj
0.9524 0 Td
(the)Tj
1.4683 0 Td
(Institute)Tj
3.583 0 Td
(for)Tj
1.389 0 Td
(Medi-)Tj
-34.9566 -1.3039 Td
(cal)Tj
1.3209 0 Td
(Microbiology,)Tj
5.862 0 Td
(Immunology)Tj
5.4538 0 Td
(and)Tj
1.7348 0 Td
(Parasitology)Tj
5.125 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(University)Tj
4.3993 0 Td
(Hospital)Tj
3.6227 0 Td
(Bonn,)Tj
2.6248 0 Td
(Bonn,)Tj
2.6306 0 Td
(Ger-)Tj
-35.2571 -1.2982 Td
(many,)Tj
2.6985 0 Td
(in)Tj
1.0375 0 Td
(accordance)Tj
4.7395 0 Td
(to)Tj
1.0205 0 Td
(the)Tj
1.474 0 Td
(European)Tj
4.1158 0 Td
(Union)Tj
2.829 0 Td
(animal)Tj
2.9707 0 Td
(welfare)Tj
3.0897 0 Td
(guidelines)Tj
4.2747 0 Td
(\(Directive)Tj
4.2292 0 Td
(2010/63/EU)Tj
-32.4791 -1.2983 Td
(and)Tj
1.7291 0 Td
(the)Tj
1.4683 0 Td
(Amsterdam)Tj
4.9606 0 Td
(Treaty:)Tj
3.0387 0 Td
(Protocol)Tj
3.6397 0 Td
(on)Tj
1.2756 0 Td
(the)Tj
1.4683 0 Td
(protection)Tj
4.3823 0 Td
(and)Tj
1.7292 0 Td
(welfare)Tj
3.0897 0 Td
(of)Tj
1.0148 0 Td
(animals)Tj
3.3335 0 Td
(N33\))Tj
2.6362 0 Td
(and)Tj
1.7348 0 Td
(all)Tj
-35.5008 -1.3039 Td
(protocols)Tj
3.9571 0 Td
(were)Tj
2.1203 0 Td
(approved)Tj
3.9741 0 Td
(by)Tj
1.1849 0 Td
(the)Tj
1.4684 0 Td
(Landesamt)Tj
4.6034 0 Td
(fu)Tj
0 Tc
0.3572 0 Td
()Tj
-0.004 Tc
0.4592 0 Td
(r)Tj
0.5896 0 Td
(Natur,)Tj
2.8119 0 Td
(Umwelt)Tj
3.4299 0 Td
(und)Tj
1.8255 0 Td
(Verbraucherschutz,)Tj
-26.7815 -1.2983 Td
(Cologne,)Tj
3.804 0 Td
(Germany)Tj
3.9855 0 Td
(\(AZ)Tj
1.8482 0 Td
(8402.04.2015.A507;)Tj
8.5039 0 Td
(8402.04.2012.A140\).)Tj
8.8497 0 Td
(All)Tj
1.3946 0 Td
(pharmacokinetic)Tj
6.9789 0 Td
(stud-)Tj
-35.3648 -1.2982 Td
(ies)Tj
1.2699 0 Td
(were)Tj
2.1203 0 Td
(reviewed)Tj
3.7984 0 Td
(and)Tj
1.7291 0 Td
(approved)Tj
3.9741 0 Td
(by)Tj
1.1792 0 Td
(AbbVie's)Tj
3.8835 0 Td
(Lake)Tj
2.1089 0 Td
(County)Tj
3.2202 0 Td
(Institutional)Tj
5.1647 0 Td
(Animal)Tj
3.2201 0 Td
(Care)Tj
2.109 0 Td
(and)Tj
1.7291 0 Td
(Use)Tj
-35.5065 -1.2983 Td
(Committee.)Tj
4.9662 0 Td
(Animal)Tj
3.2202 0 Td
(studies)Tj
2.982 0 Td
(were)Tj
2.126 0 Td
(conducted)Tj
4.4276 0 Td
(in)Tj
1.0318 0 Td
(an)Tj
1.2076 0 Td
(AAALAC)Tj
4.1556 0 Td
(accredited)Tj
4.3426 0 Td
(program)Tj
3.702 0 Td
(and)Tj
1.7292 0 Td
(veteri-)Tj
-33.8908 -1.3039 Td
(nary)Tj
2.0295 0 Td
(care)Tj
1.8709 0 Td
(was)Tj
1.7008 0 Td
(available)Tj
3.6623 0 Td
(to)Tj
1.0261 0 Td
(ensure)Tj
2.8744 0 Td
(appropriate)Tj
4.8812 0 Td
(animal)Tj
2.9707 0 Td
(care.)Tj
ET
Q
q
1 j
1 J
0.0001 w
11.9999 0 0 11.9999 200.012 326.154 cm
BT
/F16 1 Tf
-0.0033 Tc
1 TL
0 0 Td
(Preparation)Tj
5.2394 0 Td
(of)Tj
1.0677 0 Td
(Tylosin)Tj
3.3496 0 Td
(derivatives)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 200.012 309.146 cm
BT
/F9 1 Tf
-0.02 Tc
1 TL
0 0 Td
(Derivatives)Tj
4.5354 0 Td
(of)Tj
0.9807 0 Td
(Tylosin)Tj
3.1068 0 Td
(A)Tj
0.8844 0 Td
(were)Tj
2.0579 0 Td
(prepared)Tj
3.6794 0 Td
(from)Tj
2.143 0 Td
(TylA)Tj
2.1543 0 Td
(\(CAS)Tj
2.3187 0 Td
(1401-69-0\))Tj
4.4277 0 Td
(or)Tj
1.0658 0 Td
(its)Tj
1.0998 0 Td
(L-\(+\)-tartrate)Tj
5.4255 0 Td
(salt)Tj
1.4967 0 Td
(\(CAS)Tj
-35.3761 -1.3039 Td
(74610-55-2\))Tj
4.8868 0 Td
(using)Tj
2.3131 0 Td
(simple)Tj
2.7553 0 Td
(modifications)Tj
5.5275 0 Td
(of)Tj
0.9864 0 Td
(previously)Tj
4.1896 0 Td
(reported)Tj
3.532 0 Td
(procedures,)Tj
4.7225 0 Td
(as)Tj
0.9864 0 Td
(illustrated)Tj
4.0422 0 Td
(in)Tj
0.83 0.64 0.02 0 k
1.0034 0 Td
(Fig)Tj
1.4344 0 Td
(1)Tj
0 g
(.)Tj
-36.3796 -1.2982 Td
(Selective)Tj
3.5092 0 Td
(acylation)Tj
3.6907 0 Td
(of)Tj
0.9808 0 Td
(the)Tj
1.423 0 Td
(2'-alcohol)Tj
3.9911 0 Td
(\(on)Tj
1.5704 0 Td
(the)Tj
1.423 0 Td
(mycaminose)Tj
5.1193 0 Td
(sugar\))Tj
2.6192 0 Td
(is)Tj
0.8164 0 Td
(accomplished)Tj
5.5105 0 Td
(under)Tj
2.5342 0 Td
(mild)Tj
2.0182 0 Td
(con-)Tj
-35.206 -1.2983 Td
(ditions)Tj
2.8856 0 Td
(employing)Tj
4.3256 0 Td
(acid)Tj
1.8085 0 Td
(anhydrides)Tj
4.5014 0 Td
(as)Tj
0.9808 0 Td
(reagents)Tj
3.4186 0 Td
([)Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(],)Tj
1.9955 0 Td
(presumably)Tj
4.7225 0 Td
(as)Tj
0.9865 0 Td
(a)Tj
0.6349 0 Td
(consequence)Tj
5.1647 0 Td
(of)Tj
0.9808 0 Td
(neighboring-)Tj
-32.4054 -1.2983 Td
(group)Tj
2.5284 0 Td
(activation)Tj
3.9912 0 Td
(from)Tj
2.143 0 Td
(the)Tj
1.423 0 Td
(adjacent)Tj
3.4355 0 Td
(dimethylamino)Tj
6.1568 0 Td
(group)Tj
2.5285 0 Td
([)Tj
0.83 0.64 0.02 0 k
(12)Tj
0 g
(].)Tj
1.9956 0 Td
(Reaction)Tj
3.617 0 Td
(with)Tj
1.9332 0 Td
(dibutyltin)Tj
4.0025 0 Td
(oxide)Tj
-33.7547 -1.3039 Td
(forms)Tj
2.4831 0 Td
(a)Tj
0.6406 0 Td
(cyclic)Tj
2.3641 0 Td
(tin)Tj
1.2869 0 Td
(oxide)Tj
2.3301 0 Td
(between)Tj
3.4129 0 Td
(the)Tj
1.4229 0 Td
(vicinal)Tj
2.7496 0 Td
(diol)Tj
1.7065 0 Td
(pair)Tj
1.7404 0 Td
(at)Tj
0.9241 0 Td
(3)Tj
1.0545 0 Td
(and)Tj
1.6838 0 Td
(4)Tj
1.0545 0 Td
(\(mycarose)Tj
4.2122 0 Td
(sugar\);)Tj
2.829 0 Td
(this)Tj
1.6101 0 Td
(serves)Tj
2.5228 0 Td
(as)Tj
-36.0281 -1.2982 Td
(an)Tj
1.1678 0 Td
(activated)Tj
3.6397 0 Td
(intermediate)Tj
5.1307 0 Td
(for)Tj
1.3379 0 Td
(the)Tj
1.423 0 Td
(selective)Tj
3.3959 0 Td
(acylation)Tj
3.6907 0 Td
(of)Tj
0.9807 0 Td
(the)Tj
1.423 0 Td
(4-hydroxyl)Tj
4.8189 0 Td
(group)Tj
2.5285 0 Td
([)Tj
0.83 0.64 0.02 0 k
(13)Tj
0 g
(].)Tj
1.9955 0 Td
(Alkylation)Tj
4.2407 0 Td
(of)Tj
-35.773 -1.2983 Td
(this)Tj
1.61 0 Td
(site)Tj
1.5024 0 Td
(is)Tj
0.8163 0 Td
(also)Tj
1.7065 0 Td
(possible,)Tj
3.4923 0 Td
(under)Tj
2.5398 0 Td
(more)Tj
2.2733 0 Td
(forcing)Tj
2.9821 0 Td
(conditions)Tj
4.3143 0 Td
(and)Tj
1.6838 0 Td
(using)Tj
2.3073 0 Td
(active)Tj
2.4265 0 Td
(alkylating)Tj
3.9515 0 Td
(agents.)Tj
-0.004 Tc
-30.4099 -1.3039 Td
(When)Tj
2.6872 0 Td
(the)Tj
1.4683 0 Td
(2'-substituent)Tj
5.6806 0 Td
(is)Tj
0.8504 0 Td
(acetyl,)Tj
2.7269 0 Td
(a)Tj
0.652 0 Td
(free)Tj
1.7234 0 Td
(2'-hydroxyl)Tj
4.8189 0 Td
(group)Tj
2.6079 0 Td
(may)Tj
1.9275 0 Td
(be)Tj
1.1509 0 Td
(liberated)Tj
/F10 1 Tf
3.719 0 Td
(\n)Tj
/F9 1 Tf
1.4173 0 Td
(heating)Tj
3.1861 0 Td
(in)Tj
-35.8126 -1.2983 Td
(methanol.)Tj
4.2462 0 Td
(This)Tj
1.9899 0 Td
(transformation)Tj
6.2759 0 Td
(is)Tj
0.8447 0 Td
(accelerated)Tj
4.6488 0 Td
(through)Tj
3.4469 0 Td
(the)Tj
1.4684 0 Td
(addition)Tj
3.5999 0 Td
(of)Tj
1.0148 0 Td
(a)Tj
0.652 0 Td
(small)Tj
2.3301 0 Td
(amount)Tj
3.3505 0 Td
(of)Tj
1.0148 0 Td
(solid)Tj
-34.8829 -1.2983 Td
(NaHCO)Tj
ET
Q
q
1 j
1 J
0.0001 w
7.4999 0 0 6.6659 233.461 177.449 cm
BT
/F9 1 Tf
-0.0053 Tc
1 TL
0 0 Td
(3)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 237.033 179.15 cm
BT
/F9 1 Tf
-0.004 Tc
1 TL
0 0 Td
(.)Tj
0.4478 0 Td
(This)Tj
1.9843 0 Td
(straightforward)Tj
6.4289 0 Td
(sequence)Tj
3.8551 0 Td
(of)Tj
1.0148 0 Td
(transformations)Tj
6.633 0 Td
(allows)Tj
2.6986 0 Td
(for)Tj
1.3889 0 Td
(the)Tj
1.4684 0 Td
(preparation)Tj
4.9096 0 Td
(of)Tj
1.0148 0 Td
(2'-,)Tj
-35.5462 -1.3039 Td
(4-,)Tj
1.6611 0 Td
(or)Tj
1.0999 0 Td
(2'/4-modified)Tj
6.0886 0 Td
(tylosin)Tj
2.9027 0 Td
(analogs,)Tj
3.4412 0 Td
(from)Tj
2.2054 0 Td
(common)Tj
3.8437 0 Td
(intermediates,)Tj
5.9074 0 Td
(in)Tj
1.0375 0 Td
(good)Tj
2.228 0 Td
(overall)Tj
2.9026 0 Td
(yields)Tj
-33.3181 -1.2982 Td
(\()Tj
0.83 0.64 0.02 0 k
(Table)Tj
2.778 0 Td
(1)Tj
0 g
(\).)Tj
ET
Q
q
1 j
1 J
0.0001 w
11.9999 0 0 11.9999 200.012 125.972 cm
BT
/F17 1 Tf
-0.0033 Tc
1 TL
0 0 Td
()Tj
1.1291 0 Td
()Tj
/F16 1 Tf
2.1638 0 Td
(anti-)Tj
/F17 1 Tf
( \n\r)Tj
/F16 1 Tf
6.6756 0 Td
(cell)Tj
1.63 0 Td
(based)Tj
2.5748 0 Td
(screening)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 200.012 109.02 cm
BT
/F9 1 Tf
-0.01 Tc
1 TL
0 0 Td
(Compounds)Tj
5.142 0 Td
(were)Tj
2.1033 0 Td
(screened)Tj
3.6736 0 Td
(for)Tj
1.3663 0 Td
(anti-)Tj
/F10 1 Tf
()Tj
/F9 1 Tf
6.2986 0 Td
(activity)Tj
/F10 1 Tf
3.0727 0 Td
( )Tj
1.0035 0 Td
(\n)Tj
/F9 1 Tf
2.0352 0 Td
(in)Tj
1.0205 0 Td
(the)Tj
1.4513 0 Td
(A)Tj
/F15 1 Tf
0 Tc
()Tj
/F9 1 Tf
-0.01 Tc
(WOL-validated)Tj
/F10 1 Tf
7.3077 0 Td
()Tj
-34.4747 -1.3039 Td
()Tj
/F9 1 Tf
(-infected)Tj
/F10 1 Tf
5.3291 0 Td
()Tj
2.4831 0 Td
()Tj
/F9 1 Tf
4.1329 0 Td
(\(C6/36)Tj
/F10 1 Tf
2.9423 0 Td
()Tj
/F9 1 Tf
(AlbB\))Tj
3.2088 0 Td
(7-day)Tj
2.4321 0 Td
(cell-based)Tj
4.1046 0 Td
(assay)Tj
2.2337 0 Td
(which)Tj
2.6191 0 Td
(utilizes)Tj
2.9764 0 Td
(a)Tj
0.6463 0 Td
(384-well)Tj
-33.1084 -1.2982 Td
(format)Tj
2.9026 0 Td
(assay)Tj
2.2337 0 Td
(with)Tj
1.9729 0 Td
(high)Tj
1.9842 0 Td
(content)Tj
3.2258 0 Td
(imaging)Tj
3.4469 0 Td
(\(HCI\))Tj
2.6363 0 Td
(\(Operetta\))Tj
4.3539 0 Td
(as)Tj
1.0035 0 Td
(described)Tj
4.0025 0 Td
(previously)Tj
4.286 0 Td
([)Tj
0.83 0.64 0.02 0 k
(14)Tj
0 g
(].)Tj
ET
Q
q
1 j
1 J
0.0001 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.26 183.288 23.6976 re
W* n
q
183.288 0 0 23.6976 36 741.26 cm
q
/I2 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0.0001 w
7.9999 0 0 7.9999 490.167 745.795 cm
BT
/F0 1 Tf
-0.005 Tc
1 TL
0 0 Td
(Discover)Tj
3.8197 0 Td
(y)Tj
0.7157 0 Td
(of)Tj
1.0418 0 Td
(ABBV-4)Tj
3.5079 0 Td
(083)Tj
ET
Q
q
1 j
1 J
0.0001 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
163.559 34.9228 m
317.707 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
-0.005 Tc
1 TL
0 0 Td
(PLOS)Tj
2.8559 0 Td
(Neglected)Tj
4.6417 0 Td
(Tropical)Tj
3.7135 0 Td
(Disease)Tj
3.5433 0 Td
(s)Tj
0.7158 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8197 0 Td
(1/journal.pn)Tj
5.1237 0 Td
(td.00071)Tj
3.8197 0 Td
(59)Tj
0 g
2.0905 0 Td
(February)Tj
4.1599 0 Td
(28,)Tj
1.5874 0 Td
(2019)Tj
23.1805 0 Td
(3)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(13)Tj
ET
Q
endstream
endobj
45 0 obj
<>
endobj
46 0 obj
<>/XObject<>>>
endobj
49 0 obj
<>stream
x\UnETlv5V]\];vݹv' (Hs߁'J<^=wwofķop td.666FT鴄B ?L,>$KǨH:J!*A @ @ @ @ @ @ rj7]9, fѾgΜ?Ƙ1cOwЙޒ=H"f>; 4d
c|?lhN/ @PPESSSRSS/T(iS>~ *r%$d@ @ @ @ @ @ rp葉'iӤaJڵ1}k9' bCQQQѭX3~իWףj5>}6A 9@lەW6K
MMMCCC:jw|Aźp9ȑ
\I <"|T˟?BCWh&m˕۵r%*d@ @ @ @ @ @ r^b"ETUU)4l}>}j=},H]443'dy HY>ccwiPl,
DGFr
3}=
Q'y )C5hA?h,Q\]]W,Of^=Jc6P"D8 '1},ԵkۚBLӦʇ,4 d xPrfΠ~z{G \TT4\vUat 28 n~
ࠣjjҝ{%K )B
#@ @ @ @ @ @ @@9 pF{6iҔ;k֬a=[?`02dppp0e
@ @ @ @ %?*o[$
իW%Jʟ?ߍRK) (n=|Rĺڝ۷H2Q֭ԩ4W(2: DǏ
Y
h$
H"[
&NLA, ,xgM߽{4?r"o^%J|J\@ @ @ @ ٯti;##Ãـx{{)bennqփT$Q8 e%SOnzT|&Eڼ~I< e-U
ܥE#l@.]K-WM~۠@( r%Eݹj^\[O]Zp ߧWJ%>W "#Wo\E넆Tͣ=xtPdd.;t%r-2%A @ @ @ @ @ @ @ڵjPK5
hĉ$өKw@*/# PN\yySS~M
33ӧՔ
% F@q=;M)Iv"7J*!ىV Ȏc7L SW?'OgLC(.~c!Cg '&[(Qcnj}ϛvv߿(NA @ @ @ VXڝZڵ4iRN
CcclllC]2=A @ @ @ @ @ @ ֜͛7PÿnZz˗nnwnR,3|ow%
ق[;t22640,TȪqv`
P(G( ~٦}^,>jj*VV!eW̱9R牫 Du6l